End-stage renal disease developed in similar proportions of diabetics regardless of whether they had intensive or standard glycemic control.
Biomarkers apoA4, CD5L, C1QB, and IBP3 may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in T2DM.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.
There was a significant association for Trp with the event of rapid decline in eGFR.
Higher levels of sRAGE were significantly associated with incidence of DN after adjustment for duration of diabetes.
Of the children who developed acute kidney injury, 34.9% had stage 1, 45.3% had stage 2, and 19.8% had stage 3.
DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.
Valsartan reduced the incidence of microalbuminuria in IGT without increasing the incidence of hyperkalemia or renal dysfunction compared with placebo.
Poor glycemic control linked to increased prevalence and severity of periodontitis.
Use of the glucagon-like peptide-1 receptor agonist lowered 24-hour urinary albumin excretion rate by 32% over 12 weeks versus placebo.
Findings in large cohort of patients with diabetes over 4 years of follow-up.
AGEs improve RFL prediction in American-Indians with type 2 diabetes.
No change in overall prevalence from 1988 to 2014; decrease in albuminuria, increase in reduced eGFR.
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
Length of time spent in remission inversely related to risk of microvascular disease.
Renal function decline is independent factor for cardiovascular risk in patients with type 2 diabetes.
Diabetic nephropathy lesions may develop prior to the onset of clinical findings.
Athcar gel may be a treatment option for patients with treatment-resistant nephrotic syndrome.
Increase in prevalence from 2002-2013, with highest prevalence among those aged 12 to less than 18 years.
The medication significantly decreased potassium levels over 52 weeks in patients with resistant hypertension and diabetic kidney disease.
Higher urinary potassium excretion, not sodium excretion, tied to lower risk of primary end point.
AKI, albuminuria, eGFR considered separately or together can predict adverse outcomes in diabetes.
Significant association found in patients with diabetic nephropathy.
Hyperkalemia occurred in just 1.8% of patients taking finerenone 7.5 to 20 mg daily.
Nonalbuminuric chronic kidney disease was linked to increases in all-cause and cardiovascular mortality, but not albuminuria or end-stage renal disease.
Older patients with more diabetes complications have greater cognitive decline, study finds.
Increased uric acid levels were correlated with decreased HbA1c and increased prevalence of diabetic kidney disease, study finds.
Intense glycemic control was significantly linked to higher risks of cardiovascular and all-cause mortality
Among the increased risks, women with the disease had an 86% higher chance of dying from cardiovascular disease than men.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)